Researchers have developed a rejected vaccine against HIV may provide strong protection with only one dose, while vaccine developers focus on the antigen protein that reveals the presence of strange objects for the immune system. Researchers are interested in working on auxiliary factors that are used to enhance the effectiveness of the vaccine and keep it inside the body to work for as long as possible.
The vaccine developed researchers from the Massachusetts Institute of Technology and the Scripps Research Center in the United States, and included two substances that motivate the response of the immune system according to the results of the study published in the Journal of Transitional Medical Sciences (Science Translational Medicine) on June 16, and written by the American Newsweek magazine.
HIV attacks the immune system in the body, and if it is not treated, it develops into the ACQUIRED IMMUNODEFICIYCY Syndrome, known as AIDS.
The researchers found that the innovative vaccine produces a significant diversity in antibodies to anti -HIV protein compared to the use of a single auxiliary substance or not using it at the experiments conducted on mice.
This is due to the accumulation of the vaccine in the lymph nodes of the mice and its survival there for a month, giving their immune devices longer time to form antibodies against HIV.
C. Christopher Loew, author of the research author and professor of chemical engineering at the Massachusetts Institute of Technology in a statement that “what distinguishes this approach is the possibility of exposing the body to a long time, with the help of materials we know well, so it does not require different technology.”
The researchers said that the same approach can be used to develop mono-doses vaccines against other diseases, including “Kovid-19” and influenza.
Spin in the lymph nodes
Most of the vaccines given today contain auxiliary substances to increase their effectiveness, such as aluminum hydroxide, which are often used with protein vaccines, such as those given against hepatitis A and B.
The youth activates the fungal immune response to the body, helping it to form a stronger memory for the vaccine antigen in the event of a real injury.
The developed vaccine brings together a nanny particle known as “SNNB”, which in turn combines soaps derived from natural sources accredited by the American Food and Drug Administration and an enhanced inflammatory molecule.
The researchers found that the youth mixture with the “SNN” helped the HIV protein in the vaccine penetrate the protective layer of the cells surrounding the lymph nodes without decomposing, in addition to remaining intact in the contract for a period of up to 28 days.
The lymph nodes are the place where the immune cells are exposed to antigens and learn to produce antibodies to resist them.
“As a result, the bacterium cells that take place in the lymph nodes are constantly exposed to the antigen during that time period, which reaches 28 days, and time is available to refine their response to this antigen,” Loew said.
When the Researchers analyzed the RNA of the bi -cells of the fertilized mice, they found that the mice that received both the two assistants produced a more diverse group of bi -cells and antibodies compared to other rodents.
The mice that received the vaccine that contains the auxiliary workers produced more than twice the number of unique bi -cells compared to the mice that received a one -auxiliary vaccine.
The team explained that this increases the possibilities of the ability of immune devices in mice to produce antibodies against various breeds of HIV in the event of receiving a future injection.
(Tagstotranslate) (T), USA, USA